Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

The drug, which combines the compounds nirmatrelvir and ritonavir, entered human clinical trials in March 2021, just 12 months after its first synthesis—stunning speed for making a new bespoke drug.

The suit – filed in a Massachusetts district court – claims that Paxlovid (nirmatrelvir and ritonavir) infringes its 11,358,953 patent which covers "compounds and pharmaceutically acceptable ...

Paxlovid is a prescription-only oral antiviral medication containing nirmatrelvir and ritonavir. It treats mild to moderate COVID-19 symptoms and is particularly effective if you are unvaccinated.